BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fidelman N, Kerlan RK Jr. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease. AJR Am J Roentgenol 2015;205:742-52. [PMID: 26397322 DOI: 10.2214/AJR.15.14802] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Castello A, Lopci E. Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. Clin Transl Imaging 2020;8:377-92. [DOI: 10.1007/s40336-020-00384-y] [Reference Citation Analysis]
2 Zhang J, Yu Z, Li H, Yi S, Liu W, Yang Y, Wang G. Severe bile duct complication after yttrium-90 radioembolization therapy in a patient with recurrent hepatocellular carcinoma after liver transplantation: A case report. Liver Research 2021;5:33-5. [DOI: 10.1016/j.livres.2020.10.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Onizuka H, Sueyoshi E, Ishimaru H, Sakamoto I, Uetani M. Arterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome. Abdom Radiol (NY) 2017;42:2544-50. [PMID: 28493072 DOI: 10.1007/s00261-017-1168-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Zhu Q, Qiao GL, Zeng XC, Li Y, Yan JJ, Duan R, Du ZY. Elevated expression of eukaryotic translation initiation factor 3H is associated with proliferation, invasion and tumorigenicity in human hepatocellular carcinoma. Oncotarget 2016;7:49888-901. [PMID: 27340783 DOI: 10.18632/oncotarget.10222] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
5 Kantor O, Baker MS. Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. Cancer Treat Res 2016;168:165-83. [PMID: 29206369 DOI: 10.1007/978-3-319-34244-3_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Aquina CT, Eskander MF, Pawlik TM. Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. Front Oncol 2022;12:832405. [DOI: 10.3389/fonc.2022.832405] [Reference Citation Analysis]
7 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
8 Lee JM, Lee KW, Kim HC, Yi NJ, Suh KS. No touch isolation technique for the prevention of postoperative recurrence of hepatocellular carcinoma after liver transplantation-combined with trans-arterial radioembolization. Surg Oncol 2020;35:189-90. [PMID: 32890956 DOI: 10.1016/j.suronc.2020.08.024] [Reference Citation Analysis]
9 Shehta A, Lee JM, Suh KS, Kim HC, Hong SK, Cho JH, Yi NJ, Lee KW. Bridging and downstaging role of trans-arterial radio-embolization for expected small remnant volume before liver resection for hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg 2020;24:421-30. [PMID: 33234744 DOI: 10.14701/ahbps.2020.24.4.421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Cho SM, Chu HH, Kim JW, Kim JH, Gwon DI. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm. Life (Basel) 2021;11:358. [PMID: 33919658 DOI: 10.3390/life11040358] [Reference Citation Analysis]
11 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Reference Citation Analysis]
12 Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol 2017;209:277-88. [PMID: 28463538 DOI: 10.2214/AJR.17.18264] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 7.8] [Reference Citation Analysis]
13 Pasciak AS, Abiola G, Liddell RP, Crookston N, Besharati S, Donahue D, Thompson RE, Frey E, Anders RA, Dreher MR, Weiss CR. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging 2020;47:816-27. [PMID: 31741021 DOI: 10.1007/s00259-019-04588-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
14 Joo I, Kim HC, Kim GM, Paeng JC. Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know. Korean J Radiol 2018;19:209-22. [PMID: 29520178 DOI: 10.3348/kjr.2018.19.2.209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
15 Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol 2020;30:68-76. [PMID: 31727302 DOI: 10.1016/j.semradonc.2019.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
16 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Reference Citation Analysis]